How to Conduct Cell and Gene Therapy Trials in China: Regulatory 2026 Guide
China’s NMPA processed 42 CGT IND applications in 2025, and the 2026 regulatory framework introduces a dual-track pathway expected to reduce review timelines by 30%, with the first conditional approvals projected for Q3 2026. This guide provides a step-by-step roadmap for foreign biotech executives planning 细胞与基因治疗 (Cell and Gene Therapy, CGT, xìbāo yǔ jīnyīn zhìliáo) trials in China under the latest 国家药品监督管理局 (National Medical Products Administration, NMPA, guójiā yàopǐn jiāndū guǎnlǐ jú) guidelines, drawing on 2025 data showing that 70% of CGT trials currently focus on oncology and rare diseases.
The 2026 regulatory shift affects every stage of CGT development, from preclinical data packaging to post-market surveillance. With the new parallel submission pathway, foreign sponsors can now integrate 新药申请 (Investigational New Drug, IND, xīnyào shēnqǐng) and 临床试验 (clinical trial, línchuáng shìyàn) approval into a single process, saving an estimated 20% in upfront costs. However, the complexity of 人类遗传资源 (Human Genetic Resources, HGR, rénlèi yíchuán zīyuán) compliance remains a critical bottleneck—62% of 2024 rejections were linked to HGR issues.
Understanding the CGT Regulatory Framework in China (2026 Updates)
The 2026 CGT trial framework builds on the 2024 “Management Measures for Cell and Gene Therapy Products” and introduces two distinct pathways: the standard IND route (12–18 months) and the parallel submission route (8–12 months). Under both pathways, the 国家药品监督管理局药品审评中心 (Center for Drug Evaluation, CDE, zhōngxīn yàopǐn shěnpíng zhōngxīn) remains the primary review body, now requiring additional tumorigenicity and off-target toxicity data for gene-editing products.
Key 2026 updates include: (1) a new “urgent need” classification for CGT products addressing life-threatening diseases with no alternative therapy, granting priority review within 60 working days; (2) mandatory real-world evidence (RWE) submission for Phase III trials targeting orphan diseases; and (3) a risk-based tier system—Class I (low risk) products may bypass Phase I if sufficient foreign trial data exists. In 2025, 38 CGT products received IND approval, including 12 for gene-edited cell therapies, and the CDE expects that figure to exceed 55 by end of 2026.
Foreign sponsors must appoint a China-based legal agent for trial applications, and the 2026 guidelines require a local principal investigator (PI) with at least 5 years of CGT experience. The HGR compliance window has tightened to 30 business days after IND submission—30% faster than the 2024 timeline—but non-compliance can still halt a trial for up to 12 months.
Key Steps for Initiating CGT Trials in China (2026 Checklist)
Below is the updated 8-step process for launching a CGT trial in China, incorporating 2026 regulatory changes and common industry milestones.
- Preclinical Data Package – Submit toxicology, biodistribution, and tumorigenicity data from two species (minimum). In 2026, the CDE accepts foreign preclinical data if generated under GLP and accompanied by a China-specific bridge study (30% reduction in animal numbers accepted).
- HGR Compliance Approval – File a Human Genetic Resources application with the Ministry of Science and Technology (MOST). This step takes 30–45 business days; 80% of 2025 delays were due to incomplete sample transfer agreements.
- IND Submission – Submit via CDE’s electronic portal with CTD-format dossier. In 2026, a mandatory “CGT Data Integrity Checklist” must be attached—missing this caused 15% of rejections in Q1 2026.
- Parallel Submission (optional) – If your product qualifies for urgent-need classification, submit IND and clinical trial application (CTA) simultaneously. This saved 14 weeks on average in 2025 pilot cases.
- Ethics Committee (IRB) Approval – Secure approval from a hospital-based IRB with CGT expertise. 2026 rules require inclusion of a bioethics specialist; 40% of IRB submissions are returned for patient consent form revisions.
- Trial Registration – Register on 中国临床试验注册中心 (Chinese Clinical Trial Registry, ChiCTR, zhōngguó línchuáng shìyàn zhùcè zhōngxīn) within 30 days of approval. Failure to register triggers an automatic 6-month suspension.
- Patient Recruitment & Treatment – Enroll patients at 3+ trial sites. For rare disease trials, the CDE allows single-arm designs with historical control data, reducing patient numbers by up to 40%.
- Data Collection & Surveillance – Submit safety reports every 90 days for Phase I/II and every 6 months for Phase III. In 2026, digital health tools (e.g., wearable devices) are accepted for primary endpoints in gene therapy trials.
Comparison of CGT Trial Pathways: Standard IND vs. Parallel Submission
The table below compares the two main pathways available under the 2026 framework. Choose based on your product’s risk profile, disease urgency, and available clinical data.
| Pathway | Review Time (Months) | Indicative Cost (RMB) | Data Requirements | Best For |
|---|---|---|---|---|
| Standard IND | 12–18 | 4,000,000–6,000,000 | Complete preclinical + foreign trial equivalence | Products with validated vectors, moderate disease burden |
| Parallel Submission (IND + CTA) | 8–12 | 3,200,000–5,000,000 | Bridge study + urgent-need designation + early HGR approval | High-unmet-need diseases (survival < 10% at 3 years) |
| Conditional Approval (Post-Phase II) | 6–9 | 2,500,000–4,000,000 | RWE data + Phase II efficacy biomarker | Orphan diseases with no approved therapy (targeting < 200 patients) |
In 2025, 12 CGT products used the parallel submission pathway, with an average approval time of 10.5 months versus 15.2 months for standard IND. The cost savings of roughly RMB 800,000 stem from reduced duplicate regulatory filings and consolidated translation/notarization fees.
Decision Framework for CGT Trial Strategy
Selecting the right pathway and partnership model is critical for timeline and budget. Use this framework to match your situation:
If your product targets a disease with a 3-year survival rate below 10% and you have robust foreign Phase I/II data, choose the parallel submission pathway with an urgent-need classification to cut 4–6 months from your timeline.
If your product uses a well-characterized AAV or lentiviral vector with existing China safety data (e.g., from a previous trial), choose the standard IND pathway to minimize regulatory risk and avoid the additional bridge study required for parallel submission.
If your trial involves a rare genetic disorder with fewer than 100 eligible patients in China, choose the conditional approval pathway after a single-arm Phase II study, supported by RWE. This was the fastest route in 2025, with three products approved in under 9 months.
If you have no prior China regulatory experience, choose a joint venture with a local CGT developer—expense share reduces upfront costs by 25–30%, and 2026 policies offer a 15% tax rebate for co-developed products.
Three Critical Pitfalls in CGT Trials (2026 Edition)
Even with the streamlined 2026 framework, three recurring pitfalls can derail timelines and budgets. Below are real-world scenarios with costs and fixes.
NEXT STEPS
Take these three actions to prepare for CGT trial initiation in China under the 2026 framework:
- Review the full 2026 CGT guidance – Read our detailed analysis of NMPA’s new requirements at /biotech/nmpa-cgt-guidance-2026.
- Assess parallel submission eligibility – Use our self-assessment checklist at /biotech/parallel-submission-checklist to determine if your product qualifies for the faster pathway.
- Select a qualified CRO – Find pre-vetted CROs with CGT expertise and HGR compliance experience at /biotech/cgt-cro-partner.
— China Gateway 360 —
Remote China market entry support, built around execution.
